302 related articles for article (PubMed ID: 24410774)
1. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Boumpas D; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Rainer F; Pavelka K; Chartier M; Poncet C; Rauch C; Bars ML
BMC Musculoskelet Disord; 2014 Jan; 15():14. PubMed ID: 24410774
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study.
Nüßlein HG; Alten R; Galeazzi M; Lorenz HM; Nurmohamed MT; Bensen WG; Burmester GR; Peter HH; Pavelka K; Chartier M; Poncet C; Rauch C; Le Bars M
BMC Musculoskelet Disord; 2015 Jul; 16():176. PubMed ID: 26228643
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M
Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472
[TBL] [Abstract][Full Text] [Related]
4. Up to 5-year retention of abatacept in Belgian patients with moderate-to-severe rheumatoid arthritis: a sub-analysis of the international, observational ACTION study.
Westhovens R; Connolly SE; Margaux J; Vanden Berghe M; Maertens M; Van den Berghe M; Elbez Y; Chartier M; Baeke F; Robert S; Malaise M
Rheumatol Int; 2020 Sep; 40(9):1409-1421. PubMed ID: 32556473
[TBL] [Abstract][Full Text] [Related]
5. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
[TBL] [Abstract][Full Text] [Related]
6. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
7. Predictors of abatacept retention over 2 years in patients with rheumatoid arthritis: results from the real-world ACTION study.
Alten R; Mariette X; Lorenz HM; Nüßlein H; Galeazzi M; Navarro F; Chartier M; Heitzmann J; Poncet C; Rauch C; Le Bars M
Clin Rheumatol; 2019 May; 38(5):1413-1424. PubMed ID: 30790095
[TBL] [Abstract][Full Text] [Related]
8. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
Cimmino MA; Leardini G; Salaffi F; Intorcia M; Bellatreccia A; Dupont D; Beresniak A
Clin Exp Rheumatol; 2011; 29(4):633-41. PubMed ID: 21813056
[TBL] [Abstract][Full Text] [Related]
9. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
10. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial.
Schiff M; Pritchard C; Huffstutter JE; Rodriguez-Valverde V; Durez P; Zhou X; Li T; Bahrt K; Kelly S; Le Bars M; Genovese MC
Ann Rheum Dis; 2009 Nov; 68(11):1708-14. PubMed ID: 19074911
[TBL] [Abstract][Full Text] [Related]
11. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
12. The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study.
Mariette X; Alten R; Nüßlein HG; Galeazzi M; Lorenz HM; Cantagrel A; Chartier M; Poncet C; Rauch C; Le Bars M
Joint Bone Spine; 2017 Oct; 84(5):571-576. PubMed ID: 28043761
[TBL] [Abstract][Full Text] [Related]
13. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
[TBL] [Abstract][Full Text] [Related]
15. Retention of subcutaneous abatacept for the treatment of rheumatoid arthritis: real-world results from the ASCORE study: an international 2-year observational study.
Alten R; Mariette X; Flipo RM; Caporali R; Buch MH; Patel Y; Marsal S; Sanmartí R; Nurmohamed MT; Griffiths H; Peichl P; Bannert B; Chartier M; Connolly SE; Lozenski K; Rauch C
Clin Rheumatol; 2022 Aug; 41(8):2361-2373. PubMed ID: 35536413
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of abatacept in moderate to severe rheumatoid arthritis.
Cortejoso-Fernández L; Romero-Jiménez MR; Pernía-López MS; Montoro-Álvarez M; Sanjurjo-Sáez M
J Pharm Pharm Sci; 2012; 15(1):46-51. PubMed ID: 22365087
[TBL] [Abstract][Full Text] [Related]
17. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.
Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R
Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865
[TBL] [Abstract][Full Text] [Related]
18. Abatacept retention and clinical outcomes in rheumatoid arthritis: real-world data from the German cohort of the ACTION study and a comparison with other participating countries.
Alten R; Feist E; Lorenz HM; Nüßlein H; Voll RE; Chartier M; Elbez Y; Rauch C
Clin Rheumatol; 2019 Nov; 38(11):3049-3059. PubMed ID: 31300979
[TBL] [Abstract][Full Text] [Related]
19. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
[TBL] [Abstract][Full Text] [Related]
20. Abatacept retention and clinical outcomes in Austrian patients with rheumatoid arthritis: real-world data from the 2-year ACTION study.
Peichl P; Alten R; Galeazzi M; Lorenz HM; Nüßlein H; Navarro F; Elbez Y; Chartier M; Hackl R; Rauch C; Connolly SE
Wien Med Wochenschr; 2020 Apr; 170(5-6):132-140. PubMed ID: 31654156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
